Semaglutide vs tirzepatide

Semaglutide (Ozempic, Wegovy, Rybelsus) vs tirzepatide (Mounjaro, Zepbound): how they work, brands, doses, head-to-head results and side effects, side by side.

Compares semaglutide and tirzepatide. Semaglutide activates the GLP-1 receptor and is sold as Ozempic, Wegovy (injection and pill), Rybelsus and Ozempic tablets; tirzepatide activates both GIP and GLP-1 receptors and is sold as Mounjaro and Zepbound, as a weekly injection only. The page maps each brand to its approved uses, gives injection and tablet dose ranges, and summarizes placebo-controlled results (Wegovy 2.4 mg 14.9% versus 2.4% at 68 weeks; Zepbound 15 mg 20.9% versus 3.1% at 72 weeks). In the head-to-head SURMOUNT-5 trial in adults with obesity, weight loss was 20.2% with tirzepatide versus 13.7% with semaglutide at 72 weeks; SURPASS-2 showed greater A1C and weight reduction with tirzepatide in type 2 diabetes. Both trials were funded by Eli Lilly. Both drugs mainly cause stomach side effects, and combining them is not recommended.

Related pages

Get the GLPeak app

Download GLPeak on the App Store · Get GLPeak on Google Play